Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ГБОУ ВПО Северо-Западный государственный медицинский университет им. И.И.Мечникова Минздрава России. 191015, Россия, Санкт-Петербург, ул. Кирочная, д. 41
A.G.Sofronov, A.P.Savelyev, A.A.Spikina I.I.Mechnikov State Northwestern Medical University of the Ministry of Health of the Russian Federation. 191015, Russian Federation, Saint Petersburg, ul. Kirochnaia, d. 41
Список исп. литературыСкрыть список 1. Hulshoff Pol HE, Schnack HG, Mandl RCW et al. Focal gray matter density changes in schizophrenia. Arch Gen Psychiatry 2001; 58: 1118–25. 2. Wright IC, Rabe-Hesketh S, Woodruff PW et al. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry 2000; 157 (1): 16–20. 3. Gur RE, Cowell P, Turetsky BI et al. Afollow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures. Arch Gen Psychiat 1998; 55: 145–52. 4. Mathalon DH, Sullivan EV, Lim KO, Pfefferbaum A. Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study. Arch Gen Psychiatry 2001; 58: 148–57. 5. Maurice T, Urani A, Phan VL, Romieu P. The interaction between neuroactive steroids and the sigma-1 receptor function: Behavioral consequences and therapeutic opportunities. Brain Res Rev 2001; 37: 116–32. 6. Baare WF, van Oel CJ, Hulshoff Pol HE et al. Volume of brain structures in twins discordant for schizophrenia. Arch Gen Psychiatry 2001; 58 (1): 33–40. 7. Bouchard P, Quirion R. [3H]1,3-di(2-tolyl)guanidine and [3H](+) pentazocine binding sites in the rat brain: autoradiographic visualization of the putative sigma1 and sigma2 receptor subtypes. Neuroscience 1997; 76: 467–77. 8. Leitner ML, Hohmann AG, Patrick SL, Walker JM. Regional variation in the ratio of sigma 1 to sigma 2 binding in rat brain. Eur J Pharmacol 1994; 259: 65–9. 9. Quirion R, Bowen WD, Itzhak Y et al. A proposal for the classification of sigma binding sites. Trends Pharmacol Sci 1992; 13: 85–6. 10. Hanner M, Moebius FF, Flandorfer A et al. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc Natl Acad Sci USA 1996; 93: 8072–7. 11. Walker JM, Bowen WD, Walker FO et al. Sigma receptors: Biology and function. Pharmacol Rev 1996; 42: 355–402. 12. Monnet FP, Maurice T. The sigma-1 protein as a target for the nongenomic effects of neuro(active)steroids: Molecular, physiological, and behavioral aspects. J Pharmacol Sci 2006; 100: 93–118. 13. Silver H. Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Int Clin Psychopharmacol 2003; 18: 305–13. Silver H. Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Expert Opin Pharmacother 2004; 5: 2053–8. 14. Hashimoto K, Fujita Y, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: Role of sigma-1 receptors. Neuropsychopharmacology 2007; 32: 514–21. 15. Hayashi T, Su TP. Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders. CNS Drugs 2004; 18: 269–84. 16. Hayshi T, Su TP. The potential role of sigma-1 receptors in lipid transport and lipid raft reconstitution in the brain: Implication for drugabuse. Life Sci 2005; 77: 1612–24. 17. Narita N, Hashimoto K, Tomitaka S, Minabe Y. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol 1996; 307: 117–9. 18. Suhara T, Takano A, Sudo Y et al. High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry 2003; 60: 386–91. 19. Gruber S, Rathgeber K, Braunig P, Gauggel S. Stability and course of neuropsychological deficits in manic and depressed bipolar patients compared to patients with major depression. J Affect Disord 2007. 20. Hashimoto K, Ishiwata K. Sigma receptor ligands: Possible application as therapeutic drugs and as radiopharmaceuticals. Curr Pharm Des 2006; 12: 3857–76. 21. Дубницкая Э.Б. Опыт применения флувоксамина (феварина) при психогенных депрессиях. Психиатрия и психофармакотерапия. 2005; 2 (7): 77–8. / Dubnitskaia E.B. Opyt primeneniia fluvoksamina (fevarina) pri psikhogennykh depressiiakh. Psikhiatriia i psikhofarmakoterapiia. 2005; 2 (7): 77–8. [in Russian] 22. Костюкова Е.Г., Граненов Г.М., Андрейчик Л.А. и др. Сравнительная эффективность флувоксамина и амитриптилина при лечении умеренной и тяжелой депрессии. В сб.: Новые достижения в терапии психических заболеваний. М., 2002; с. 305–15. / Kostiukova E.G., Granenov G.M., Andreichik L.A. i dr. Sravnitel'naia effektivnost' fluvoksamina i amitriptilina pri lechenii umerennoi i tiazheloi depressii. V sb.: Novye dostizheniia v terapii psikhicheskikh zabolevanii. M., 2002; s. 305–15. [in Russian]